Vistagen Therapeutics Analyst Ratings
Vistagen Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 269.23% | Stifel | → $12 | Initiates Coverage On | → Buy |
| 09/05/2023 | 823.08% | Maxim Group | $30 → $30 | Maintains | Buy |
| 08/07/2023 | 823.08% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 07/26/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | 176.92% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | 84.62% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | 84.62% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | -78.46% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 269.23% | Stifel | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 09/05/2023 | 823.08% | Maxim 集团 | 30 美元 → 30 美元 | 维护 | 买 |
| 08/07/2023 | 823.08% | Maxim 集团 | → 30 美元 | 升级 | 持有 → 买入 |
| 07/26/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 07/22/2022 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 2021 年 5 月 20 日 | 176.92% | 贝尔德 | → 9 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 2 月 18 日 | 84.62% | 杰富瑞集团 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 01/04/2021 | — | 威廉布莱尔 | 升级 | 市场表现 → 跑赢大盘 | |
| 2020 年 8 月 10 日 | 84.62% | 宙斯盾资本 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 08/28/2019 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 07/22/2019 | -78.46% | 查丹资本 | 22 美元 → 0.7 美元 | 降级 | 买入 → 中性 |
What is the target price for Vistagen Therapeutics (VTGN)?
Vistagen Therapeutics（VTGN）的目标价格是多少？
The latest price target for Vistagen Therapeutics (NASDAQ: VTGN) was reported by Stifel on November 14, 2023. The analyst firm set a price target for $12.00 expecting VTGN to rise to within 12 months (a possible 269.23% upside). 3 analyst firms have reported ratings in the last year.
Stifel于2023年11月14日公布了Vistagen Therapeutics（纳斯达克股票代码：VTGN）的最新目标股价。该分析公司将目标股价定为12.00美元，预计VTGN将在12个月内升至12个月内（可能上涨269.23％）。去年有3家分析公司公布了评级。
What is the most recent analyst rating for Vistagen Therapeutics (VTGN)?
分析师对Vistagen Therapeutics（VTGN）的最新评级是多少？
The latest analyst rating for Vistagen Therapeutics (NASDAQ: VTGN) was provided by Stifel, and Vistagen Therapeutics initiated their buy rating.
Stifel提供了Vistagen Therapeutics（纳斯达克股票代码：VTGN）的最新分析师评级，Vistagen Therapeutics启动了买入评级。
When is the next analyst rating going to be posted or updated for Vistagen Therapeutics (VTGN)?
Vistagen Therapeutics（VTGN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Vistagen Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Vistagen Therapeutics的最新评级是在2023年11月14日公布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Vistagen Therapeutics (VTGN) correct?
分析师对Vistagen Therapeutics（VTGN）的评级正确吗？
While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a initiated with a price target of $0.00 to $12.00. The current price Vistagen Therapeutics (VTGN) is trading at is $3.25, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Vistagen Therapeutics（VTGN）评级是启动的，目标股价为0.00美元至12.00美元。Vistagen Therapeutics（VTGN）目前的交易价格为3.25美元，在分析师的预测区间内。
译文内容由第三方软件翻译。